Market Place
Sourcing Support
Ainos Expands Patent Portfolio with Shareholder Technology
28 Oct 2024 //
ACCESSWIRE
Ainos Highlights VELDONA Advancements in Podcast
24 Oct 2024 //
ACCESSWIRE
Ainos Advances Healthcare Innovations With AI Nose And Velnova
07 Oct 2024 //
ACCESSWIRE
Water Tower Research Highlights Ainos VELDONA Clinical Trial
20 Sep 2024 //
ACCESSWIRE
Ainos Plans Taiwan Clinical Study For VELDONA As Treatment For Oral Warts In HIV
17 Sep 2024 //
ACCESSWIRE
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
27 Aug 2024 //
ACCESSWIRE
Ainos CEO Highlights AI Nose Achievements In Shareholder Letter
26 Aug 2024 //
ACCESSWIRE
Ainos Unveils AI Nose For Smart Manufacturing And Factory Safety
19 Aug 2024 //
GLOBENEWSWIRE
Ainos To Participate In Water Tower Research Fireside Chat
12 Aug 2024 //
ACCESSWIRE
Ainos Secures Patent Licenses For AI Nose And Point-Of-Care Testing
09 Aug 2024 //
ACCESSWIRE
Ainos Concludes Growth Financing From Lind Partners
06 Aug 2024 //
ACCESSWIRE
Ainos Reports Second Quarter 2024 Financial Results
05 Aug 2024 //
ACCESSWIRE
Ainos To Study New VELDONA-Based Potential Animal Health Drug
15 May 2024 //
ACCESSWIRE
Ainos Reports First Quarter 2024 Financial Results
13 May 2024 //
ACCESSWIRE
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
07 May 2024 //
ACCESSWIRE
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
02 Jan 2024 //
ACCESSWIRE
Ainos, Nisshinbo Micro Devices and Inabata Initiate Ph 2 of VOC Co-development
26 Dec 2023 //
ACCESSWIRE
Ainos, Inc. Announces Stock Consolidation
12 Dec 2023 //
ACCESSWIRE
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch
28 Nov 2023 //
ACCESSWIRE
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA
21 Nov 2023 //
ACCESSWIRE
Ainos Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
ACCESSWIRE
Ainos Signs MoU for Contract Trials to Conduct Clinical Study of VELDONA
06 Nov 2023 //
ACCESSWIRE
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million
25 Sep 2023 //
ACCESSWIRE
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA
18 Sep 2023 //
ACCESSWIRE
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
05 Sep 2023 //
ACCESSWIRE
Ainos Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
ACCESSWIRE
Ainos Issues Mid-Year Business Update Letter to Shareholders
27 Jun 2023 //
ACCESSWIRE
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny
14 Jun 2023 //
ACCESSWIRE
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements
07 Jun 2023 //
ACCESSWIRE
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
30 May 2023 //
ACCESSWIRE
Ainos Appoints Amanda Sung as New Chief Financial Officer
17 May 2023 //
ACCESSWIRE
Ainos Reports First Quarter 2023 Financial Results
12 May 2023 //
ACCESSWIRE
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
31 Mar 2023 //
ACCESSWIRE
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate
14 Mar 2023 //
ACCESSWIRE
Ainos Announces US$3 Million Convertible Notes Private Placement
13 Mar 2023 //
ACCESSWIRE
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA
23 Jan 2023 //
ACCESSWIRE
Ainos Issues 2023 Shareholder Letter
17 Jan 2023 //
ACCESSWIRE
Ainos Publishes Data Demonstrating its VELDONA Formulation`s Potential
21 Nov 2022 //
PRNEWSWIRE
Ainos Pursues Partners to Accelerate Five Candidates VELDONA to PIII Trials
31 Oct 2022 //
ACCESSWIRE
Ainos Announces Positive Results from Additional Preclinical Study Its Low-dose
30 Sep 2022 //
ACCESSWIRE
